Stay updated on GVAX & Pembrolizumab in MMR-p CRC Clinical Trial
Sign up to get notified when there's something new on the GVAX & Pembrolizumab in MMR-p CRC Clinical Trial page.

Latest updates to the GVAX & Pembrolizumab in MMR-p CRC Clinical Trial page
- Check2 days agoChange DetectedThe only visible change is the updated revision tag: Revision: v3.3.4 replacing the previous Revision: v3.3.3 on the Study Documents section. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedAdded a Locations section showing Maryland as a study site; updated the page to revision v3.3.3.SummaryDifference0.2%

- Check52 days agoChange DetectedA clarifying line about publications being provided voluntarily has been added to the Publications section, and a revision tag (v3.3.2) appears, while the previous wording for v3.2.0 was removed.SummaryDifference0.1%

- Check60 days agoChange DetectedRemoved the government funding status notice banner from the page; this banner previously warned that information may not be up to date. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check81 days agoChange DetectedThe updates appear to be cosmetic UI/layout changes with no modifications to study details, eligibility criteria, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check103 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference4%

Stay in the know with updates to GVAX & Pembrolizumab in MMR-p CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GVAX & Pembrolizumab in MMR-p CRC Clinical Trial page.